Literature DB >> 27225495

Biopharmaceutical Evaluation of Novel Cyclosporine A Nano-matrix Particles for Inhalation.

Hideyuki Sato1, Hiroki Suzuki1, Keisuke Yakushiji1, Jennifer Wong2, Yoshiki Seto1, Robert K Prud'homme3, Hak-Kim Chan4, Satomi Onoue5.   

Abstract

PURPOSE: This study was undertaken to evaluate the biopharmaceutical properties of cyclosporine A (CsA)-loaded nano-matrix particles for inhalation.
METHODS: Nano-matrix particles of CsA with mannitol (nCsAm) were prepared by a flash nano-precipitation technique employing a multi-inlet vortex mixer and evaluated in terms of physicochemical properties, anti-inflammatory effect in the rat model of airway inflammation, pharmacokinetic behavior, and distributions of CsA to side-effect-related organs after intratracheal administration.
RESULTS: In nCsAm, spherical nano-particles of CsA were covered with mannitol and the mean particle size was 1.3 μm. The in vitro Next Generation Impactor analysis demonstrated fine inhalation performance with a fine particle fraction value of 65.8%. Intratracheal nCsAm (100 μg-CsA/rat) significantly attenuated the recruitment of inflammatory cells into the airway in the rat model of airway inflammation, followed by suppression of the inflammatory biomarkers. After intratracheal nCsAm at a pharmacologically effective dose (100 μg-CsA/rat), there was a 42-47-fold decrease in the distribution of CsA to side-effect-related organs such as the kidney and liver compared with oral CsA at a toxic dose (10 mg-CsA/kg), potentially leading to avoidance of systemic side-effects of CsA.
CONCLUSION: Upon these findings, nCsAm prepared with the flash nano-precipitation technique could be a novel dosage form of CsA for inhalation therapy of airway inflammation with a better safety margin.

Entities:  

Keywords:  anti-inflammatory effect; cyclosporine A; inhalation; nano-matrix particles; pharmacokinetic control

Mesh:

Substances:

Year:  2016        PMID: 27225495     DOI: 10.1007/s11095-016-1949-6

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  52 in total

Review 1.  Pulmonary drug delivery systems: recent developments and prospects.

Authors:  H M Courrier; N Butz; Th F Vandamme
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2002       Impact factor: 4.889

Review 2.  Calcineurin inhibitor nephrotoxicity.

Authors:  Maarten Naesens; Dirk R J Kuypers; Minnie Sarwal
Journal:  Clin J Am Soc Nephrol       Date:  2009-02       Impact factor: 8.237

3.  Inhaled cyclosporine and pulmonary function in lung transplant recipients.

Authors:  Soleyah Groves; Marek Galazka; Bruce Johnson; Timothy Corcoran; Avelino Verceles; Edward Britt; Nevins Todd; Bartley Griffith; Gerald C Smaldone; Aldo Iacono
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-02       Impact factor: 2.849

4.  Cyclosporin: use outside transplantation.

Authors:  A W Thomson; G H Neild
Journal:  BMJ       Date:  1991-01-05

5.  Low dose cyclosporin-A therapy in Behçet's disease.

Authors:  H Sajjadi; M Soheilian; H Ahmadieh; K Hassanein; M Parvin; M Azarmina; V Ehyaee; B Amiransari
Journal:  J Ocul Pharmacol       Date:  1994

6.  Nephrotoxicity of cyclosporin A in hereditary hypertriglyceridemic rats.

Authors:  M Bohdanecká; O Schück; M Chadimová; J Sedivý; A Glagolicová; J Skibová; J Kunes; Z Dobesová; M Stuchlík; J Veselá; L Kazdová
Journal:  Physiol Res       Date:  1999       Impact factor: 1.881

7.  A randomized trial of inhaled cyclosporine in lung-transplant recipients.

Authors:  Aldo T Iacono; Bruce A Johnson; Wayne F Grgurich; J Georges Youssef; Timothy E Corcoran; Deidre A Seiler; James H Dauber; Gerald C Smaldone; Adriana Zeevi; Samuel A Yousem; John J Fung; Gilbert J Burckart; Kenneth R McCurry; Bartley P Griffith
Journal:  N Engl J Med       Date:  2006-01-12       Impact factor: 91.245

8.  Lung deposition and pharmacokinetics of nebulized cyclosporine in lung transplant patients.

Authors:  T E Corcoran; R Niven; W Verret; S Dilly; B A Johnson
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-05-13       Impact factor: 2.849

Review 9.  New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone.

Authors:  Norma A Bobadilla; Gerardo Gamba
Journal:  Am J Physiol Renal Physiol       Date:  2007-04-11

10.  Pharmacokinetics of SDZ 64-412, a novel antiasthmatic agent, following intravenous, oral, and inhalation dosing in the rat.

Authors:  S B Charnick; Z Yu; L V Athill; A H Karara; F L Tse; D T Lau
Journal:  Biopharm Drug Dispos       Date:  1994-05       Impact factor: 1.627

View more
  2 in total

1.  Porous mannitol carrier for pulmonary delivery of cyclosporine A nanoparticles.

Authors:  Sharon Shui Yee Leung; Jennifer Wong; Heloisa Victorino Guerra; Kevin Samnick; Robert K Prud'homme; Hak-Kim Chan
Journal:  AAPS J       Date:  2017-01-09       Impact factor: 4.009

2.  Towards a Continuous Manufacturing Process of Protein-Loaded Polymeric Nanoparticle Powders.

Authors:  Stefan Schiller; Andrea Hanefeld; Marc Schneider; Claus-Michael Lehr
Journal:  AAPS PharmSciTech       Date:  2020-10-06       Impact factor: 3.246

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.